Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 0.25
LCI's Cash-to-Debt is ranked lower than
82% of the 719 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.89 vs. LCI: 0.25 )
Ranked among companies with meaningful Cash-to-Debt only.
LCI' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.01  Med: 1.84 Max: N/A
Current: 0.25
Equity-to-Asset 0.31
LCI's Equity-to-Asset is ranked lower than
86% of the 660 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.62 vs. LCI: 0.31 )
Ranked among companies with meaningful Equity-to-Asset only.
LCI' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.17  Med: 0.71 Max: 0.92
Current: 0.31
-0.17
0.92
Interest Coverage 0.63
LCI's Interest Coverage is ranked lower than
98% of the 641 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 101.29 vs. LCI: 0.63 )
Ranked among companies with meaningful Interest Coverage only.
LCI' s Interest Coverage Range Over the Past 10 Years
Min: 0.63  Med: 47.21 Max: 1094.14
Current: 0.63
0.63
1094.14
Piotroski F-Score: 3
Altman Z-Score: 1.30
Beneish M-Score: -2.71
WACC vs ROIC
15.65%
14.10%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % 9.82
LCI's Operating Margin % is ranked higher than
56% of the 672 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.86 vs. LCI: 9.82 )
Ranked among companies with meaningful Operating Margin % only.
LCI' s Operating Margin % Range Over the Past 10 Years
Min: -7.5  Med: 9.74 Max: 55.67
Current: 9.82
-7.5
55.67
Net Margin % -3.61
LCI's Net Margin % is ranked lower than
77% of the 673 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.73 vs. LCI: -3.61 )
Ranked among companies with meaningful Net Margin % only.
LCI' s Net Margin % Range Over the Past 10 Years
Min: -8.39  Med: 5.87 Max: 36.85
Current: -3.61
-8.39
36.85
ROE % -4.27
LCI's ROE % is ranked lower than
74% of the 690 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.66 vs. LCI: -4.27 )
Ranked among companies with meaningful ROE % only.
LCI' s ROE % Range Over the Past 10 Years
Min: -9.5  Med: 8.85 Max: 39.56
Current: -4.27
-9.5
39.56
ROA % -1.32
LCI's ROA % is ranked lower than
71% of the 721 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.48 vs. LCI: -1.32 )
Ranked among companies with meaningful ROA % only.
LCI' s ROA % Range Over the Past 10 Years
Min: -6.58  Med: 4.71 Max: 35.21
Current: -1.32
-6.58
35.21
ROC (Joel Greenblatt) % 13.07
LCI's ROC (Joel Greenblatt) % is ranked lower than
51% of the 710 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.44 vs. LCI: 13.07 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
LCI' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -12.51  Med: 27.67 Max: 133.12
Current: 13.07
-12.51
133.12
3-Year Revenue Growth Rate 40.60
LCI's 3-Year Revenue Growth Rate is ranked higher than
93% of the 600 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.00 vs. LCI: 40.60 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
LCI' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -20.8  Med: 12.9 Max: 70.8
Current: 40.6
-20.8
70.8
3-Year EBITDA Growth Rate 66.40
LCI's 3-Year EBITDA Growth Rate is ranked higher than
93% of the 574 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.70 vs. LCI: 66.40 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
LCI' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -92  Med: 25.7 Max: 153.4
Current: 66.4
-92
153.4
3-Year EPS without NRI Growth Rate 37.70
LCI's 3-Year EPS without NRI Growth Rate is ranked higher than
84% of the 541 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.50 vs. LCI: 37.70 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
LCI' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -58.1  Med: 25.9 Max: 206.7
Current: 37.7
-58.1
206.7
GuruFocus has detected 4 Warning Signs with Lannett Co Inc $LCI.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» LCI's 10-Y Financials

Financials (Next Earnings Date: 2017-05-01 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

LCI Guru Trades in Q1 2016

Richard Snow 174,065 sh (New)
Ronald Muhlenkamp 406,600 sh (New)
David Dreman 70 sh (New)
Jim Simons 21,500 sh (New)
Joel Greenblatt Sold Out
Paul Tudor Jones Sold Out
» More
Q2 2016

LCI Guru Trades in Q2 2016

Steven Cohen 216,200 sh (New)
Richard Snow 630,165 sh (+262.03%)
David Dreman Sold Out
Jim Simons Sold Out
Ronald Muhlenkamp 404,405 sh (-0.54%)
» More
Q3 2016

LCI Guru Trades in Q3 2016

Ken Fisher 7,650 sh (New)
Paul Tudor Jones 15,677 sh (New)
Joel Greenblatt 280,182 sh (New)
Richard Snow 1,638,072 sh (+159.94%)
Steven Cohen Sold Out
Ronald Muhlenkamp 270,930 sh (-33.01%)
» More
Q4 2016

LCI Guru Trades in Q4 2016

Joel Greenblatt 618,606 sh (+120.79%)
Ronald Muhlenkamp 504,379 sh (+86.17%)
Richard Snow 2,525,635 sh (+54.18%)
Ken Fisher Sold Out
Paul Tudor Jones 9,900 sh (-36.85%)
» More
» Details

Insider Trades

Latest Guru Trades with LCI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:NAS:HRTX, OTCPK:NPPNY, NAS:IPXL, NAS:FLXN, NAS:AMPH, NAS:DEPO, NAS:MNTA, OTCPK:TWMJF, OTCPK:APHQF, NYSE:DPLO, OTCPK:ACBFF, NAS:LBIO, NAS:INNL, NAS:SCLN, NAS:SCMP, NAS:ACET, NAS:COLL, NAS:SGYP, NAS:KPTI, OTCPK:GNMLF » details
Traded in other countries:LN5.Germany,
Lannett Co Inc develops, manufactures, packages, markets and distributes generic versions of branded pharmaceutical products. Its products include solid oral dosage forms, including oral solutions, nasal, topicals or parentarels.

Lannett Co Inc was incorporated in 1942 under the laws of the Commonwealth of Pennsylvania, and reincorporated in 1991 as a Delaware corporation. The Company develops, manufactures, markets and distributes generic versions of branded pharmaceutical products. The Company manufactures solid oral dosage forms, including tablets and capsules, extended release, topicals, oral solutions and distributes parenteral as well as ophthalmics. All of the products are currently manufactured and sold are prescription products. The Company's products containing Levo are produced and marketed with 12 varying potencies. In addition to generic Levo tablets, it also market and distribute Unithroid tablets, a branded version of Levo, which is produced and marketed with 11 varying potencies. Both generic Levo tablets and Unithroid tablets are manufactured by JSP. Lannett began buying generic Levo from JSP and selling it to its customers in April 2003. Levo tablets are used to treat hypothyroidism and other thyroid disorders. Levo remains the most prescribed drugs in the U.S. and is used by over 13 million patients of various ages and demographic backgrounds. In distribution of these products, the Company competes with two branded Levo products-Abbott Laboratories Synthroid(r) and Monarch Pharmaceuticals Levoxyl(r)- as well as generic products from Mylan and Sandoz. Digoxin tablets are produced and marketed with two different potencies, 0.125mg and 0.25mg per tablet. This product is manufactured by JSP. Lannett began buying this product from JSP and selling it to its customers in September 2002. Digoxin tablets are used to treat congestive heart failure in patients of various ages and demographic backgrounds. The Company distributes two products containing Butalbital. Lannett has manufactured and sold one of the products, Butalbital with Aspirin and Caffeine capsules, for more than nine years. The other Butalbital product, Butalbital with Aspirin, Caffeine and Codeine Phosphate capsules, is manufactured by JSP. Lannett began buying this product from JSP and selling it to its customers in December 2002. Both Butalbital products, which are in orally administered capsule dosage forms, are prescribed to treat tension headaches caused by contractions of the muscles in the neck and shoulder area and migraine. Primidone tablets are produced and marketed with two different potencies, 50mg and 250mg tablets. Lannett has developed and manufacture Primidone tablets and began selling Primidone 50mg tablets in June 2001. In addition, the Company has been manufacturing and selling Primidone 250mg tablets for more than seven years. Both Primidone products, which are in orally administered tablet dosage forms, are prescribed to treat convulsion and seizures in epileptic patients of all ages and demographic backgrounds. Lannett sell its pharmaceutical products to generic pharmaceutical distributors, drug wholesalers, chain drug retailers, private label distributors, ma

Top Ranked Articles about Lannett Co Inc

CEO Buys Shares of Lannett Insider invests in 10,000 shares
Lannett Co. Inc. (NYSE:LCI) CEO Arthur Bedrosian purchased 10,000 shares of the company for $20 per share on Feb. 6, according to a Form 4 filing with the Securities and Exchange Commission. He now owns 688,909 shares of the company. Read more...

Ratios

vs
industry
vs
history
Forward PE Ratio 6.64
LCI's Forward PE Ratio is ranked higher than
93% of the 89 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.46 vs. LCI: 6.64 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PB Ratio 1.43
LCI's PB Ratio is ranked higher than
77% of the 761 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.93 vs. LCI: 1.43 )
Ranked among companies with meaningful PB Ratio only.
LCI' s PB Ratio Range Over the Past 10 Years
Min: 0.61  Med: 1.67 Max: 6.39
Current: 1.43
0.61
6.39
PS Ratio 1.18
LCI's PS Ratio is ranked higher than
77% of the 727 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.85 vs. LCI: 1.18 )
Ranked among companies with meaningful PS Ratio only.
LCI' s PS Ratio Range Over the Past 10 Years
Min: 0.48  Med: 1.46 Max: 7.05
Current: 1.18
0.48
7.05
Price-to-Free-Cash-Flow 7.26
LCI's Price-to-Free-Cash-Flow is ranked higher than
89% of the 228 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 24.42 vs. LCI: 7.26 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
LCI' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 3.22  Med: 21.22 Max: 526.92
Current: 7.26
3.22
526.92
Price-to-Operating-Cash-Flow 5.40
LCI's Price-to-Operating-Cash-Flow is ranked higher than
89% of the 290 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.18 vs. LCI: 5.40 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
LCI' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 2.89  Med: 15.6 Max: 274.76
Current: 5.4
2.89
274.76
EV-to-EBIT 25.06
LCI's EV-to-EBIT is ranked lower than
64% of the 545 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 20.11 vs. LCI: 25.06 )
Ranked among companies with meaningful EV-to-EBIT only.
LCI' s EV-to-EBIT Range Over the Past 10 Years
Min: -259.1  Med: 12.05 Max: 348.4
Current: 25.06
-259.1
348.4
EV-to-EBITDA 13.50
LCI's EV-to-EBITDA is ranked higher than
59% of the 573 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.30 vs. LCI: 13.50 )
Ranked among companies with meaningful EV-to-EBITDA only.
LCI' s EV-to-EBITDA Range Over the Past 10 Years
Min: -2299.1  Med: 11 Max: 681
Current: 13.5
-2299.1
681
Shiller PE Ratio 29.85
LCI's Shiller PE Ratio is ranked higher than
69% of the 159 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 44.64 vs. LCI: 29.85 )
Ranked among companies with meaningful Shiller PE Ratio only.
LCI' s Shiller PE Ratio Range Over the Past 10 Years
Min: 23.48  Med: 82 Max: 1389
Current: 29.85
23.48
1389
Current Ratio 2.00
LCI's Current Ratio is ranked lower than
56% of the 614 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.31 vs. LCI: 2.00 )
Ranked among companies with meaningful Current Ratio only.
LCI' s Current Ratio Range Over the Past 10 Years
Min: 0.99  Med: 2.39 Max: 10.52
Current: 2
0.99
10.52
Quick Ratio 1.61
LCI's Quick Ratio is ranked lower than
54% of the 613 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.73 vs. LCI: 1.61 )
Ranked among companies with meaningful Quick Ratio only.
LCI' s Quick Ratio Range Over the Past 10 Years
Min: 0.26  Med: 1.68 Max: 9.3
Current: 1.61
0.26
9.3
Days Inventory 134.00
LCI's Days Inventory is ranked lower than
59% of the 626 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 115.23 vs. LCI: 134.00 )
Ranked among companies with meaningful Days Inventory only.
LCI' s Days Inventory Range Over the Past 10 Years
Min: 68.82  Med: 107.64 Max: 165.34
Current: 134
68.82
165.34
Days Sales Outstanding 126.87
LCI's Days Sales Outstanding is ranked lower than
79% of the 571 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 77.23 vs. LCI: 126.87 )
Ranked among companies with meaningful Days Sales Outstanding only.
LCI' s Days Sales Outstanding Range Over the Past 10 Years
Min: 78.9  Med: 98.94 Max: 171.98
Current: 126.87
78.9
171.98
Days Payable 47.81
LCI's Days Payable is ranked lower than
72% of the 522 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 73.13 vs. LCI: 47.81 )
Ranked among companies with meaningful Days Payable only.
LCI' s Days Payable Range Over the Past 10 Years
Min: 44.61  Med: 74.51 Max: 88.36
Current: 47.81
44.61
88.36

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -8.30
LCI's 3-Year Average Share Buyback Ratio is ranked lower than
64% of the 441 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.00 vs. LCI: -8.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
LCI' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -37  Med: -6.3 Max: -0.1
Current: -8.3
-37
-0.1

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 0.68
LCI's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
92% of the 314 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.37 vs. LCI: 0.68 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
LCI' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.57  Med: 1.38 Max: 5.6
Current: 0.68
0.57
5.6
Price-to-Median-PS-Value 0.83
LCI's Price-to-Median-PS-Value is ranked higher than
77% of the 664 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.20 vs. LCI: 0.83 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
LCI' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.46  Med: 1.22 Max: 7.61
Current: 0.83
0.46
7.61
Earnings Yield (Greenblatt) % 4.01
LCI's Earnings Yield (Greenblatt) % is ranked higher than
58% of the 788 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.86 vs. LCI: 4.01 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
LCI' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.3  Med: 6.85 Max: 20
Current: 4.01
0.3
20
Forward Rate of Return (Yacktman) % 102.51
LCI's Forward Rate of Return (Yacktman) % is ranked higher than
99% of the 364 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.76 vs. LCI: 102.51 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
LCI' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -12.1  Med: 4.35 Max: 130.6
Current: 102.51
-12.1
130.6

More Statistics

Revenue (TTM) (Mil) $641.5
EPS (TTM) $ -0.63
Beta2.39
Short Percentage of Float49.37%
52-Week Range $16.75 - 39.99
Shares Outstanding (Mil)37.19

Analyst Estimate

Jun17 Jun18 Jun19 Jun20
Revenue (Mil $) 678 669 676 681
EPS ($) 3.42 3.17 3.35 3.40
EPS without NRI ($) 3.42 3.17 3.35 3.40
EPS Growth Rate
(Future 3Y To 5Y Estimate)
6.00%
Dividends per Share ($)
» More Articles for LCI

Headlines

Articles On GuruFocus.com
Weekly CEO Buys Highlights Feb 13 2017 
CEO Buys Shares of Lannett Feb 08 2017 
Lannet's Lopinavir, Ritonavir Approved to Treat HIV in US Jan 05 2017 
Teva: Good Value, Questionable Management? Jan 02 2017 
Integer Investments: Akorn Has 100% Upside Potential Jan 01 2017 
Richard Snow Boosts Kinder Morgan, Cuts Macy's Nov 16 2016 
Snow Capital Management's Top 5 New Buys May 12 2016 
A Short-Term Problem Creates Long-Term Opportunity in Lannett Company Jan 12 2016 
Healthcare Company Lannett Offers Compelling Value Oct 13 2015 
Royce 100 Fund Shareholder Letter Sep 20 2015 

More From Other Websites
Is Lannett (LCI) a Great Stock for Value Investors? Mar 21 2017
Lannett Co., Inc. breached its 50 day moving average in a Bearish Manner : LCI-US : March 20, 2017 Mar 20 2017
The Zacks Analyst Blog Highlights: Inogen, OraSure Technologies, Lannett and Cardiovascular Systems Mar 10 2017
Lannett To Participate At Four Upcoming Investor Conferences Feb 27 2017
Lannett Announces Addition To Management Team Feb 23 2017
FDA gives Lannett more time to make its case for ADHD drug Feb 22 2017
Lannett Provides Further Update On Methylphenidate ER Tablets Feb 22 2017
Will Lannett (LCI) Continue to Surge Higher? Feb 16 2017
Weekly CEO Buys Highlights Feb 13 2017
CEO Buys Shares of Lannett Feb 08 2017
LANNETT CO INC Financials Feb 08 2017
Lannett Co., Inc. :LCI-US: Earnings Analysis: Q2, 2017 By the Numbers : February 7, 2017 Feb 07 2017
Board Member at Beleaguered Burrito Chain Buys Shares After Barron’s Releases Grim Cover Story,... Feb 07 2017
Lannett Announces Successful Completion Of ERP System Extraction Feb 07 2017
Affimed (AFMD) Shows Strength: Stock Moves 8.1% Higher Feb 06 2017
AcelRx Pharmaceuticals (ACRX) in Focus: Stock Rises 5.3% Feb 06 2017
LANNETT CO INC Files SEC form 10-Q, Quarterly Report Feb 03 2017
LANNETT CO INC Files SEC form 8-K, Results of Operations and Financial Condition Feb 02 2017
Edited Transcript of LCI earnings conference call or presentation 1-Feb-17 9:30pm GMT Feb 01 2017
Lannett tops Street 2Q forecasts Feb 01 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)